Weight Management
April 20, 2026
·
7 min read
read
Does Ozempic Cause Hair Loss? What the Research Says
Primary KW: ozempic hair loss | Secondary KW: semaglutide hair loss, GLP-1 hair loss, weight loss injection hair loss singapore
Primary KW: ozempic hair loss | Secondary KW: semaglutide hair loss, GLP-1 hair loss, weight loss injection hair loss singapore
If you're taking semaglutide — or considering it — and you've heard about hair shedding, you're not alone. "Ozempic hair loss" has become one of the most searched concerns among people using GLP-1 medications for weight management. The good news: the evidence suggests that for most people, it is temporary, manageable, and largely preventable with the right approach.
This article breaks down what the research actually says, why hair loss occurs on GLP-1 medications, who is most at risk, and what you can do about it.
The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021;384:989–1002) — the pivotal study that supported FDA approval of Wegovy (semaglutide 2.4 mg) for weight management — enrolled 1,961 adults and tracked adverse events over 68 weeks. Hair loss (alopecia) was reported as an adverse event in approximately 3% of participants in the semaglutide arm, compared to around 1% in the placebo group.
At first glance, 3% sounds small. But it's roughly three times the background rate, which matters when you're the one losing hair.
Real-world data points higher. A 2024 disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) by Godfrey et al. (JEADV 2025; PMID 38925559) found statistically increased reporting of alopecia for both semaglutide and tirzepatide — but not for older GLP-1 agents like liraglutide, dulaglutide, or exenatide. This is significant: it suggests the effect may be tied to the degree of weight loss (greater with newer high-dose agents) rather than to GLP-1 receptor activation itself.
A retrospective cohort study by Burke et al. (JAAD 2025;92:1141–1143) confirmed a notable association between GLP-1RA use and alopecia incidence. And a systematic review by Branyiczky et al. (Int J Dermatol 2025) found that across reviewed studies, 11.3% of GLP-1 patients reported new-onset or worsening hair loss — considerably higher than trial-reported figures, likely due to under-reporting in clinical settings.
Desai et al. (Int J Dermatol 2024;63:1128–1130) have called for larger prospective studies specifically designed to track hair outcomes — acknowledging that current evidence, while consistent, is largely observational.
Bottom line: Hair loss is a real, documented side effect of semaglutide-based weight management. It is more common in real-world use than clinical trial figures suggest, and it appears to be more frequent with high-dose agents that produce rapid, substantial weight loss.
The most plausible explanation is telogen effluvium — not a direct drug effect on hair follicles, but a downstream consequence of rapid weight loss.
Here's the biology: Your hair follicles cycle through three phases — anagen (active growth), catagen (transition), and telogen (resting/shedding). In a healthy state, about 85–90% of your follicles are in anagen at any given time. Under physiological stress — including caloric restriction, rapid weight change, surgery, illness, or major hormonal shifts — a disproportionate number of follicles are prematurely pushed into the telogen phase. Two to four months later, when those follicles reach the end of their resting phase and shed, you experience a noticeable increase in hair loss.
Semaglutide produces, by design, a significant caloric deficit. The STEP 1 trial showed a mean body weight reduction of 14.9% over 68 weeks — roughly 15 kg for an average participant. That kind of rapid, sustained weight loss closely resembles the conditions that follow bariatric surgery, which is well-documented to cause telogen effluvium in a significant proportion of patients (Malkud S, J Clin Diagn Res 2015; PMC4606321).
Contributing factors include:
There is also an important sex difference: tirzepatide's prescribing information reports hair loss in 7.1% of female patients versus 0.5% of male patients in clinical trials (placebo: 1.3% female, 0% male). This likely reflects women's greater hormonal sensitivity in follicle cycling.
The reassuring news: telogen effluvium is typically self-limiting. Once the triggering stress — in this case, the period of most rapid weight loss — stabilises, follicles gradually return to anagen. Most patients see shedding peak around 2–4 months after the onset of significant weight loss, with noticeable improvement over the following 3–6 months.
Crucially, shedding does not mean permanent follicle death. If you are seeing diffuse, generalised hair thinning (rather than patchy bald spots), the follicles are very likely still intact — they're just not growing yet.
Complete regrowth typically occurs within 6–12 months, provided the nutritional and hormonal conditions support recovery.
1. Prioritise protein intake. Even when your appetite is suppressed, aim for 1.2–1.5 g of protein per kilogram of body weight daily. Protein is non-negotiable for hair follicle health. Lean meats, fish, eggs, legumes, and dairy are your allies.
2. Monitor micronutrients. Ask your doctor to check ferritin (iron stores), zinc, vitamin D, and thyroid function before starting treatment and again at 3–6 months. Deficiencies are treatable. A ferritin level below 30 µg/L is strongly associated with telogen effluvium even in the absence of anaemia.
3. Don't stop your medication without consulting your doctor. Hair loss is distressing, but it is not a reason to discontinue an otherwise effective and medically appropriate treatment. Discuss concerns with your prescribing physician first.
4. Avoid additional stressors. Harsh chemical treatments, excessive heat styling, and tight hairstyles can worsen shedding in a vulnerable phase. Be gentle with your hair during the first 6 months of treatment.
5. Consider a dermatology referral if shedding is severe. A dermatologist can distinguish telogen effluvium from other causes (androgenetic alopecia, alopecia areata) and recommend targeted treatments including topical minoxidil if appropriate.
Based on available evidence, hair loss is more likely if you:
These are risk factors to discuss with your doctor before starting treatment — not reasons to avoid effective weight management.
Q: Is Ozempic-related hair loss permanent?
A: In the vast majority of cases, no. The pattern observed — diffuse shedding starting 2–4 months after significant weight loss — is consistent with telogen effluvium, which is self-limiting and reversible. Follicles typically resume normal cycling once weight stabilises and nutritional status is optimised.
Q: How long does hair loss last on semaglutide?
A: Most patients report the heaviest shedding phase lasts 3–6 months. Visible regrowth typically follows within 6–12 months. Individual timelines vary based on nutritional status, rate of weight loss, and other factors.
Q: Should I stop Ozempic if I'm losing hair?
A: Do not stop your medication without speaking to your prescribing doctor first. Hair loss, while distressing, is generally temporary. Your doctor can assess whether it is treatment-related and recommend supportive measures. Abruptly stopping a weight management programme has its own health consequences.
Q: Does everyone on semaglutide lose hair?
A: No. Clinical trial data shows alopecia in approximately 3% of semaglutide patients, versus ~1% in placebo groups. Real-world figures from systematic reviews are higher (~11%), but the majority of patients do not experience significant hair loss.
Q: Can I prevent hair loss while on Ozempic?
A: Partially. Ensuring adequate protein intake, monitoring iron and micronutrient levels, and avoiding additional stressors can significantly reduce risk. Complete prevention is not guaranteed, particularly if rapid weight loss is occurring — but severity can often be minimised.
Q: Does hair grow back after stopping semaglutide?
A: For most patients, hair recovers regardless of whether medication is continued or stopped — what matters is whether the triggering stress (rapid weight loss, nutritional deficiency) has resolved. Regrowth typically occurs within 6–12 months.
Hair shedding on Ozempic and semaglutide is real, documented in clinical trials and real-world data, and more common than many patients expect. The mechanism is well understood: rapid weight loss triggers telogen effluvium, compounded by nutritional deficiencies that reduced appetite can create.
The prognosis is almost universally good. For the vast majority of patients, hair loss is temporary, self-limiting, and fully reversible with proper nutritional support and time.
If you're concerned about hair health during GLP-1 treatment, speak to a doctor who can assess your individual risk profile, check your nutrient levels, and create a plan that supports both your weight goals and overall wellbeing.
Ready to start your weight management journey with proper medical oversight?
Zoey provides clinician-supervised GLP-1 weight management programmes in Singapore, with ongoing monitoring that includes nutritional guidance.
👉 Start your consultation at zoey.sg
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.
Citations:
